We analyzed ICANS patients and, in line with previous findings [6, 10, 12], elevated serum IL-6 levels correlated with CRS (Additional file 1: Fig. S1E), and CRS rapidly resolved after administration of the IL-6 receptor blocker tocilizumab [15]. The gene discussed is IL6; the disease is congenital rubella syndrome.